BJMO - volume 12, issue 10, march 2018
M. Albersen MD, PhD, MD , PhD
It has become of yearly tradition of BMUC to put a tumor type in the spotlight that is often overlooked at (inter)national symposia. This year, Prof. Maarten Albersen gave an overview of the current treatment landscape of penile cancer.
BJMO - volume 10, issue 6, september 2016
F. Baekelandt MD, W. Everaerts MD, PhD, M. Albersen MD, PhD, B. Van Cleynenbreugel MD, PhD, U. Milenkovic MD, C. Assenmacher MD, S. Joniau MD, PhD
BRCA2 mutation carriers generally present with prostate cancer at a younger age, with more aggressive disease and with a higher risk of nodal involvement or distant metastases at diagnosis. We present a patient with metastatic castrate resistant prostate cancer with a BRCA2 gene mutation and its clinical significance for daily practice.
(BELG J MED ONCOL 2016;10(6):223–227)
Read moreBJMO - volume 9, issue 7, december 2015
H. Van Den Bossche MD, R. Kokx MD, M. Albersen MD, PhD, C. Assenmacher MD, H. Van Poppel MD, PhD, S. Joniau MD, PhD
High-intensity focused ultrasound has been used as an alternative treatment for prostate cancer, as both primary or salvage treatment. It is considered a minimally invasive treatment modality. We recently needed to care for two patients with severe osteomyelitis of the pubic bone as a result of a prostatopubic fistula, after they underwent salvage high-intensity focused ultrasound treatment post-radiotherapy.
(BELG J MED ONCOL 2015;9(7):290–95)
Read more
Top
